智通财经7月29日讯（记者 封其娟）智通财经近日获悉，信达澳亚基金副总王建华因家庭原因即将离职，目前相关离 职流程已在推进中，离任公告或在近期披露。离任或许早有预兆，截至今年1月9日，王建华已无在管公募产品，任期 内产品亏损明显。 值得注意的是，包括王建华在内，信达澳亚近一年已有5位副总卸任。从分管条线来看，其中4位均属"投研系"。 不同于王建华，冯明远、宋加旺均因工作安排卸任副总，去"行政化"是为更聚焦投研工作。与此同时，二人分别转任 首席投资官、固收首席投资官。另外，李淑彦因个人原因离任副总并清仓在管产品。据中基协，李淑彦已从信达澳亚 从业人员公示名单中移除。 入职信达澳亚后，王建华历任3只公募产品。因内部调整，王建华于2024年1月卸任信澳新目标基金经理。今年1月， 同一原因，王建华又同时卸任信澳新财富、信澳恒盛2只产品，自此便无在管公募产品。除了信澳恒盛为偏债混合产 品，另外2只产品均为灵活配置型产品。 据中基协，信达澳亚目前登记在册的31名公募基金经理中已无王建华，但位于公司21名专户投资经理的名单之列。 据wind数据，王建华在任期间，信澳新财富、信澳新目标、信澳恒盛A分别亏损20.31%、33. ...

近日，信达澳亚基金宣布原副总经理王建华因个人原因离任，这已是该公司今年以来离任的第3位副总经理 投资时间网、标点财经研究员 齐文健 时隔不到3个月，这家千亿公募基金公司又有一位副总经理离任。 近日，信达澳亚基金发布高级管理人员变更公告称，原副总经理王建华因个人原因离任，并未转任公司其他工作岗位。这已是该公司今年前7个月离任的 第3位副总经理。 除此之外，信达澳亚基金旗下公募基金管理规模遭遇大幅缩水。Wind数据显示，截至2025年二季度末，该公司公募基金管理规模为1030.06亿元，较2024 年末减少344.44亿元。 年内已有3位副总经理离任 公募基金公司的副总经理职位变动能有多频繁？ 7月30日，信达澳亚基金宣布，王建华因个人原因离任副总经理。截至离任，他的副总经理任期为4年4个月。据悉，他在任期间主要负责该公司混合资产 投资部的工作。 此外，信澳优势行业（A类份额024473、C类份额024889）7月14日披露的招募说明书，王建华还是信达澳亚基金联席投资总监。在加入信达澳亚基金之 前，他曾在交通银行工作多年。 公开资料显示，王建华还曾是信达澳亚基金的公募基金经理，先后管理信澳新财富（A类份额0036 ...

Core Viewpoint - Mini funds that were once struggling on the brink of liquidation are now making a significant comeback by investing in trending sectors and future industries [1][5]. Group 1: Fund Performance and Growth - In Q2, 15 public funds experienced a scale increase of over 10 times, with some funds surging by more than 14,600% [2][5]. - The fund "Tongtai Industrial Upgrade," managed by Wang Xiu, saw its scale grow from under 10,000 yuan to over 14.4 million yuan, marking a growth of over 1,461,747% [3]. - "Changcheng Pharmaceutical Industry Selection," with a nearly 120% return, increased its scale from 3.6 million yuan to 1.132 billion yuan, a growth of over 30 times [4]. Group 2: Investment Strategies and Sector Focus - Many mini funds have undergone significant portfolio adjustments, shifting from traditional sectors to high-growth areas like robotics, innovative pharmaceuticals, and computing power [6][7]. - The fund "Zhongou Digital Economy," managed by Feng Ludan, shifted its focus from robotics and smart driving to computing power, changing eight of its top ten holdings [8]. - The "Yongying Medical Health" fund transitioned its focus from medical services to innovative pharmaceuticals, with top holdings including Shutaishen and Rejing Bio, the latter having a year-to-date increase of 523.75% [9]. Group 3: Early Positioning in Future Industries - Fund companies are using mini funds to target emerging sectors such as deep-sea technology and controllable nuclear fusion, positioning themselves ahead of the curve [10][11]. - The "Yongying Manufacturing Upgrade" fund is heavily invested in controllable nuclear fusion, anticipating significant growth in the sector by 2025, with potential annual investments reaching 30 to 50 billion yuan [12]. - The "Yongying Qiyuan" fund focuses on the deep-sea technology industry, with major holdings in companies involved in deep-sea materials and applications [12].

Core Insights - Mini funds that were previously struggling on the brink of liquidation are now achieving significant growth by investing in trending sectors and future industries [1][2] - In Q2, 15 public funds experienced a scale increase of over 10 times, with 13 of them being mini funds that had less than 200 million yuan in scale at the end of Q1 [3] Fund Performance - The fund managed by Wang Xiu, Tongtai Industrial Upgrade, saw its scale grow from less than 10,000 yuan to over 1.44 billion yuan, marking a growth of over 14,600 times [2] - Changcheng Pharmaceutical Industry Selected Fund achieved a scale increase of over 30 times, reaching 1.132 billion yuan, with a notable focus on innovative drugs [2] - Other funds like CITIC Prudential Stable Hong and Xinao Core Selection also reported substantial growth, with increases of nearly 574 times and 20 times, respectively [3] Investment Strategies - Many mini funds are undergoing significant portfolio adjustments, shifting from traditional sectors to high-growth areas such as robotics and innovative pharmaceuticals [4][6] - The fund managed by Feng Ludan, China Europe Digital Economy, made substantial changes in its holdings, focusing on AI infrastructure and applications while reducing exposure to robotics [4] - The Yongying Medical Health Fund shifted its focus entirely to innovative drugs, with top holdings showing significant price increases [6] Emerging Technologies - Fund managers are positioning themselves in early-stage industries like deep-sea technology and controllable nuclear fusion, indicating a proactive approach to future investment opportunities [7][8] - Funds such as Yongying Manufacturing Upgrade and Huafu Tianxin are heavily investing in companies related to controllable nuclear fusion, anticipating significant market growth by 2025 [7] - The Yongying Qiyuan Fund is focusing on the deep-sea technology sector, with investments in materials and applications related to deep-sea exploration and extraction [8]